'Cibinqo (abrocitinib),' the third JAK inhibitor to be introduced for atopic dermatitis in Korea, will be reimbursed starting this month. Healthcare professionals have expressed high expectations for Cibinqo, as the drug has accumulated robust data in treating severe atopic dermatitis.

On the 11th, the Korean pharmaceutical company Hanmi Pharmaceutical held a press conference to celebrate the reimbursement of Cibinqo, an oral atopic dermatitis treatment, at the Seoul Dragon City Hotel in Yongsan-gu, Seoul. Professor Yong-Hyun Jang of the Department of Dermatology at Kyungpook National University Hospital explained the background and significance of Cinbinqo's reimbursement for atopic dermatitis in Korea.